Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082980" target="_blank" >RIV/65269705:_____/25:00082980 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143852
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/hon.70155" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/hon.70155</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/hon.70155" target="_blank" >10.1002/hon.70155</a>
Alternative languages
Result language
angličtina
Original language name
Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties
Original language description
Testing to discontinue imatinib already started some years after the advent of this new CML therapy. Since that time, despite many trials and studies in this field, there are still significant gaps, and many fundamental questions remain unanswered. Probably the most intriguing is the persistence of minimal residual disease, which does not lead to disease recurrence in all patients. Nevertheless, today's understanding enables TKI to be safely discontinued in eligible patients outside clinical trials. Notwithstanding, TKI cessation still has to be considered and indicated with caution, taking into account several important viewpoints, like: (i) why stop the therapy in a particular patient, and are all the eligible patients willing to cease the treatment? (ii) Will all the TKI-related side effects relieve upon stopping? (iii) are there any side effects after discontinuing treatment? This review covers extensively all aspects of treatment cessation, like history, theoretical background, eligible patients, monitoring after treatment discontinuation, trigger for retreatment, therapy restart, predictive factors for successful therapy cessation, immunological aspects, potential complications of TKI withdrawal, late molecular relapses, blast crisis development, kinetics of preexisting TKI-related side effects and laboratory values, and quality of life upon treatment cessation. The art of treatment cessation is to select the best candidate based on many diverse facts and information, and follow the patient in the most rational way with smartly anticipating the potential risks and side effects.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NU22-03-00136" target="_blank" >NU22-03-00136: Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after two-step dose reduction in patients with chronic myeloid leukemia (A prospective multi-centre phase II clinical trial - HALF)</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Hematological Oncology
ISSN
0278-0232
e-ISSN
1099-1069
Volume of the periodical
43
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
22
Pages from-to
"e70155"
UT code for WoS article
001613593100001
EID of the result in the Scopus database
2-s2.0-105021396331